Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label Study to Compare the Safety and Pharmacokinetics of Various Formulations of Orally Administered Superoxide Dismutase Mimetic GC4711 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 or GC4711 in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase 1, Open-label Study to Compare the Safety and Pharmacokinetics of Various Formulations of Orally Administered Superoxide Dismutase Mimetic GC4711 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 or GC4711 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avasopasem manganese (Primary) ; Rucosopasem manganese (Primary) ; Rucosopasem manganese (Primary)
  • Indications Cancer; Head and neck cancer; Stomatitis
  • Focus Adverse reactions; First in man
  • Sponsors Galera Therapeutics

    • Most Recent Events

    • 01 Mar 2021 Status changed from recruiting to completed.
    • 11 Sep 2019 Planned End Date changed from 1 Feb 2019 to 1 Dec 2020.
    • 11 Sep 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top